Retraction: Targeting Neural-Restrictive Silencer Factor Sensitizes Tumor Cells to Antibody-Based Cancer Immunotherapy in Vitro via Multiple Mechanisms

Journal of Immunology - United States
doi 10.4049/jimmunol.1190073
Full Text
Abstract

Available in full text

Date
Authors
Publisher

The American Association of Immunologists

Related search

Retraction: Modulation of CD59 Expression by Restrictive Silencer Factor-Derived Peptides in Cancer Immunotherapy for Neuroblastoma

Cancer Research
Cancer ResearchOncology
2013English

Targeting HSF1 Sensitizes Cancer Cells to HSP90 Inhibition

Oncotarget
Oncology
2013English

Targeting Treg Cells in Cancer Immunotherapy

European Journal of Immunology
AllergyImmunology
2019English

Targeting Natural Killer Cells for Tumor Immunotherapy

Frontiers in Immunology
AllergyImmunology
2020English

Targeting Tumor-Intrinsic Hexosamine Biosynthesis Sensitizes Pancreatic Cancer to Anti-Pd1 Therapy

Journal of Clinical Investigation
Medicine
2019English

Targeting PI3K in Cancer: Impact on Tumor Cells, Their Protective Stroma, Angiogenesis, and Immunotherapy

Cancer Discovery
Oncology
2016English

Neuron-Restrictive Silencer Factor–mediated Downregulation of Μ-Opioid Receptor Contributes to the Reduced Morphine Analgesia in Bone Cancer Pain

Pain
NeurologyAnesthesiologyPain MedicinePharmacology
2017English

Quercetin Sensitizes Human Glioblastoma Cells to Temozolomide in Vitro via Inhibition of Hsp27

Acta Pharmacologica Sinica
MedicinePharmacology
2014English

Improving Cancer Immunotherapy by Targeting Tumor-Induced Immune Suppression

Cancer and Metastasis Reviews
Cancer ResearchOncology
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy